Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SETD8/KMT5A drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SETD8 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Active enzyme domain for methyltransferase assays. |
View SETD8 Products |
| Gene Delivery | SETD8 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View SETD8 Products |
| Benchmark Ab | Anti-SETD8 Recombinant Antibody Recombinant positive control antibody for Western Blot, IP, and ChIP assays. |
View SETD8 Products |
| Validator | SETD8 siRNA Set For target knockdown and specificity verification in cell-based assays. |
View SETD8 Products |
| Related Target A | Histone H4 Natural substrate for SETD8-mediated monomethylation (H4K20me1). High-purity recombinant protein. |
View Histone H4 Products |
| Related Target B | p53 Non-histone substrate. SETD8-mediated methylation of p53 at K382 suppresses its transcriptional activity. |
View p53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Enzymatic Activity & Selectivity Screening | Recombinant SETD8 active catalytic domain strictly verified by mass spectrometry and sequence analysis, ensuring high assay reproducibility. |
| Subfamily Off-target Profiling | Homolog panel proteins (other lysine methyltransferases like G9a, EZH2, and SUV39H1) available with >95% purity for counter-screening. |
| Lack of Controls | Sequence-verified benchmark target antibodies and validated positive controls included in the assay validation workflow. |
| False Positives in HTS | Validated siRNA sets included for orthogonal loss-of-function validation in cellular models. |
Live SETD8/KMT5A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SETD8/KMT5A therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum epigenetic inhibitors to highly selective small molecule inhibitors and PROTACs (Proteolysis Targeting Chimeras). As first-generation chemical probes reach advanced preclinical stages, the next wave of R&D is targeting cancer immunotherapy combinations and overcoming drug resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Consortia, Biotech Startups | Solid Tumors, Hematological Malignancies | Enzymatic Selectivity Assay (Need high-purity active SETD8 and homolog panel) |
| PROTACs / Degraders | Targeted Protein Degradation Pioneers | Castration-Resistant Prostate Cancer, NSCLC | Ubiquitination & Degradation Kinetics (Need Lentivirus for stable reporter cell lines) |
| Combination Therapies | Clinical Stage Biopharma | Immunotherapy-Resistant Tumors | Synergy Validation (Need validated siRNA and pathway-related targets like p53) |